Google and Apple Warn U.S. Visa Holders to Avoid International Travel Amid Lengthy Embassy Delays 
Niigata Set to Approve Restart of Japan’s Largest Nuclear Power Plant in Major Energy Shift 
Harris Associates Open to Revised Paramount Skydance Bid for Warner Bros Discovery 
Delta Air Lines President Glen Hauenstein to Retire, Leaving Legacy of Premium Strategy 
Boeing Seeks FAA Emissions Waiver to Continue 777F Freighter Sales Amid Strong Cargo Demand 
Apple Opens iPhone to Alternative App Stores in Japan Under New Competition Law 
Bridgewater Associates Plans Major Employee Ownership Expansion in Milestone Year 
U.S. Lawmakers Urge Pentagon to Blacklist More Chinese Tech Firms Over Military Ties 
FDA Fast-Tracks Approval of Altria’s on! PLUS Nicotine Pouches Under New Pilot Program 
Nike Shares Slide as Margins Fall Again Amid China Slump and Costly Turnaround 
Roche CEO Warns US Drug Price Deals Could Raise Costs of New Medicines in Switzerland 
Maersk Vessel Successfully Transits Red Sea After Nearly Two Years Amid Ongoing Security Concerns 
7-Eleven CEO Joe DePinto to Retire After Two Decades at the Helm 
Moore Threads Unveils New GPUs, Fuels Optimism Around China’s AI Chip Ambitions 
JPMorgan’s Top Large-Cap Pharma Stocks to Watch in 2026 
Trump Signals Push for Lower Health Insurance Prices as ACA Premium Concerns Grow 
Citi Appoints Ryan Ellis as Head of Markets Sales for Australia and New Zealand 
ALBUQUERQUE, N.M., June 29, 2016 -- Mesa Biotech Inc., a privately-held, molecular diagnostic company that has developed a testing platform designed specifically for point-of-care (POC) infectious disease diagnosis, today announced the formation of their scientific advisory board (SAB). Approved by the executive leadership team and board of directors, the SAB is chartered to advise on the development and commercialization of Mesa Biotech's infectious disease assay platform. Dr. Steve Young, of TriCore Reference Laboratories in Albuquerque, New Mexico, will lead a world class team with over 150 years of combined experience in infectious diseases and molecular point of care diagnostics.
Dr. Steve Young, Director of Research and clinical trials at TriCore Reference Laboratory has completed over 100 FDA in vitro diagnostic device trials/market evaluations. He is also diplomat of the American Board of Medical Microbiology and holds a Ph.D. from the University of New Mexico.
"We are thrilled to have such a talented and experienced scientific advisory board providing critical expertise to the Mesa Biotech team," said Hong Cai, co-founder and CEO. "The background and experience of our advisory board is going to be invaluable as we commercialize our current technology for the rapid, testing of influenza A/B, as well as to help us successfully reach our goal of bringing transformative diagnostics to the point of care."
Dr. Young said, "I am excited to be working alongside such an exceptionally talented group of doctors, researchers, and experts in the field of virology, pathology, microbiology and immunology. With this talented team of individuals we will help Mesa Biotech become a leader in the Point of Care Molecular diagnostic space".
About TriCore Reference Laboratories
TriCore Reference Laboratories is an independent clinical reference laboratory providing a complete range of services to health care professionals across the Southwest as well as pathology consultation services to clinicians across the country. TriCore also provides investigational services including FDA-regulated clinical trials, IRB-approved studies, device and diagnostic instrument testing, serving global biotech firms as well as academic clients. For more information, visit www.tricore.org
About Mesa Biotech Inc.
Mesa Biotech is an emerging molecular diagnostic company, bringing the superior diagnostic performance of nucleic acid amplification to the point-of-care (POC). Mesa Biotech's diagnostic system consists of a portable, palm-sized dock and a disposable, assay-specific test cassette. This patented system will allow healthcare professionals to obtain actionable, laboratory quality results at the POC in 30 minutes or less with greater sensitivity and specificity than many current infectious disease rapid immunodiagnostic tests. Mesa's technology development has been funded to date by a series of grants and private equity investments totaling approximately $30 million. The company is preparing for Series A funding in 2016 and expects to obtain FDA approval for its first product, an influenza assay and dock, in 2017. For more information visit http://www.mesabiotech.com.
CONTACT: Carol Biondi
[email protected]
505-379-5616
